


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



in which

- R denotes Hal, $-C\equiv C-H$, $-C\equiv C-A$ or OA,
- R¹ denotes H, =O, Hal, A, OH, OA, A-COO-, Ph-(CH₂)_n-COO-, cycloalkyl-(CH₂)_n-COO-, A-CONH-, A-CONA-, Ph-CONA-, N₃, NH₂, NO₂, CN, COOH, COOA, CONH₂, CONHA, CON(A)₂, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA or =CF₂,
- X, X' each, independently of one another, denote CH, CHal or N,
- Y denotes R⁴ or Hal,
- Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,
- R² denotes H, Hal or A,
- R³ denotes H or A,
- R⁴ denotes OH, OA, A-COO-, NHA, NHAr, NAA', Het or $-NH-CHR^5-COOR^3$,
- R⁵ denotes H, A, $-CHR^3-OH$, (CH₂)_n-Ph, (CH₂)_n-COOH, (CH₂)_n-CONH₂, (CH₂)_p-NH₂, (CH₂)_n-NH(=NH)NH₂, (CH₂)_n-Het¹ or (CH₂)_n-SR³,
- Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, OH, OA, CN,

COOH, COOA and/or carbonyl oxygen (=O),

Het¹ denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, OH, OA and/or CN,

A, A' each, independently of one another, denote unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Ar denotes naphthyl, biphenyl, or phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂N(R³)₂, S(O)_nA, -[C(R³)₂]_n-COOR³ or -O-[C(R³)₂]_p-COOR³,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

p denotes 1, 2, 3, 4 or 5,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1 in which
R denotes Hal or -C≡C-H,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 or 2 in which
R¹ denotes H, =O, Hal, A, OH or OA,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-3~~ in which
R¹ denotes OH,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
5. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-4~~ in which
X denotes CH or N,
X' denotes CH,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
6. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-5~~ in which
R² denotes H or Hal,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
7. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-6~~ in which
R³ denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-7~~ in which

Het denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, OH and/or OA,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-8~~ in which

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indolyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, OH and/or OA,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-9~~ in which

Het¹ denotes an unsubstituted mono- or bicyclic aromatic heterocycle having 1 to 2 N, O and/or S atoms,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-10~~ in which

R^5 denotes H or A,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers
thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-11~~ in which

Ar denotes naphthyl, or phenyl which is unsubstituted or mono-,
di- or trisubstituted by Hal, A, OR^3 , $N(R^3)_2$, NO_2 , CN, $COOR^3$
or $CON(R^3)_2$,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers
thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-12~~ in which


Ar denotes phenyl,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers
thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-13~~ in which

R denotes Hal or $-C\equiv C-H$,
 R^1 denotes OH,
X denotes CH or N,
 X' denotes CH,
Y denotes R^4 or Hal,
 R^2 denotes H or Hal,
 R^3 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

R^4 denotes OH, OA, A-COO-, NHA, NHA_{Ar}, NAA', Het, -NH-CHR⁵-COOR³ or -NH-CHR⁵-COOH,
 R^5 denotes H or A,
 Het denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, OH and/or OA,
 A, A' each, independently of one another, denote unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
 Hal denotes F, Cl, Br or I,
 n denotes 0, 1, 2 or 3,
 p denotes 1, 2, 3, 4 or 5,
 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15. (Currently Amended) Compounds of the formula Ia



according to claim 1 ~~one or more of Claims 1-14~~

in which

R denotes Hal or -C≡C-H,
 R^1 denotes OH,
 X denotes CH or N,
 X' denotes CH,

Y	denotes R ⁴ or Hal,
R ²	denotes H or Hal,
R ³	denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms,
R ⁴	denotes OH, OA, A-COO-, NHA, NAA', Het, -NH-CHR ⁵ -COOR ³ or -NH-CHR ⁵ -COOH,
R ⁵	denotes H or A,
Het	denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, OH and/or OA,
A, A'	each, independently of one another, denote unbranched, branched or cyclic alkyl having 1-12 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
Hal	denotes F, Cl, Br or I,
n	denotes 0, 1, 2 or 3,
p	denotes 1, 2, 3, 4 or 5,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

16. (Original) Compounds according to Claim 1 selected from the group
- 1-N-(4-chlorophenyl)-2-N-{4-[(2-dimethylaminoethanoyl)methylamino]-phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-(4-chlorophenyl)-2-N-{4-[(2-(N-methyl,N-butylamino)-ethanoyl)-methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-(4-chlorophenyl)-2-N-{4-[(2-(morpholin-4-yl)ethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-(4-chlorophenyl)-2-N-{4-[(2-(4-hydroxypiperidin-1-yl)-ethanoyl)-methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-(4-chlorophenyl)-2-N-{4-[(2-(2,6-dimethylmorpholin-4-yl)-ethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-(3-cyclohexylmethylpiperidin-1-yl)ethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-diethylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-(*N*-methyl,*N*-ethylamino)ethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-(2-methylimidazol-1-yl)ethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-ethynylphenyl)-2-N-{4-[(2-dimethylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{2-fluoro-4-[(2-dimethylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{5-[(2-dimethylaminoethanoyl)methylamino]pyridin-2-yl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-acetoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

methyl (2R,4R)-2-[(4-({1-[1-(4-chlorophenyl)carbonyl]-4-hydroxypyrrolidin-2-yl}methanoyl)amino)phenyl]methylcarbonyl)methylamino]-4-methylpentanoate,

1-N-(4-chlorophenyl)-2-N-{4-[(2-ethylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-chloroethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-cyclohexylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,


1-N-(4-chlorophenyl)-2-N-{4-[(2-methylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-isopropylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-(4-chlorophenyl)-2-N-{4-[(2-*tert*-butylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-cyclopentylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-cyclopropylmethylaminoethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-hydroxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-methoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-ethoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-propoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{4-[(2-butoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-ethynylphenyl)-2-N-{4-[(2-methoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{2-fluoro-4-[(2-methoxyethanoyl)methylamino]phenyl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
 1-N-(4-chlorophenyl)-2-N-{5-[(2-methoxyethanoyl)methylamino]pyridin-2-yl}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,


and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

17. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~Claims 1-16~~ and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that
 - a) a compound of the formula II



in which R, R¹, R², X and X' have the meanings indicated in Claim 1,

is reacted with a compound of the formula III




in which

Y and R³ have the meanings indicated in Claim 1,


or

b) a compound of the formula IV



in which R, R¹, R², R³, X and X' have the meanings indicated in Claim 1,

is reacted with a compound of the formula V




in which Y has the meaning indicated in Claim 1 and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

or

c) a compound of the formula VI




in which R and R¹ have the meanings indicated in Claim 1,

and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

is reacted with a compound of the formula VII.



in which R², R³, X, X' and Y have the meanings indicated in Claim 1,

and/or

a base or acid of the formula I is converted into one of its salts.

18. (Currently Amended) Compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 16~~ as inhibitors of coagulation factor Xa.
19. (Currently Amended) Compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 16~~ as inhibitors of coagulation factor VIIa.
20. (Currently Amended) Medicaments comprising at least one compound of the formula I according to claim 1 ~~one or more of Claims 1 to 16~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
21. (Currently Amended) Medicaments comprising at least one compound of the formula I according to claim 1 ~~one or more of Claims 1 to 16~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
22. (Currently Amended) Use of compounds according to claim 1 ~~one or more of Claims 1 to 16~~ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
23. (Currently Amended) Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound of the formula I according to claim 1 ~~one or more of Claims 1 to 16~~ and/or pharmaceutically usable

derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

24. (Currently Amended) Use of compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 16~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.